Mirtazapine Tablet, Film Coated
NDC Package 57237-009-30
Package Information
Mirtazapine tablets is mirtazapine is used to treat depression. This formulation utilizes a tablet, film coated delivery system. Marketed by Rising Pharma Holdings, Inc., this product is identified by NDC 57237-009 and is authorized under FDA application ANDA076921.
Identification & Billing
- RxCUI: 311725 - mirtazapine 15 MG Oral Tablet
- RxCUI: 311726 - mirtazapine 45 MG Oral Tablet
- RxCUI: 314111 - mirtazapine 30 MG Oral Tablet
- RxCUI: 476809 - mirtazapine 7.5 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 57237 - Rising Pharma Holdings, Inc.
- 57237-009 - Mirtazapine
- 57237-009-30 - 30 TABLET, FILM COATED in 1 BOTTLE
- 57237-009 - Mirtazapine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (57237-009). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 57237-009-30 identifies a specific commercial package of 30 tablet, film coated in 1 bottle of Mirtazapine, a human prescription drug labeled by Rising Pharma Holdings, Inc.. This tablet, film coated is formulated for oral use and contains mirtazapine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Rising Pharma Holdings, Inc. on October 22, 2004. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Mirtazapine is used to treat depression. It improves mood and feelings of well-being. Mirtazapine is an antidepressant that works by restoring the balance of natural chemicals (neurotransmitters) in the brain.
How is this Rising Pharma Holdings, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 57237000930. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.